Meredith Herring, NP
Payments from drug & device makers
What this record shows
Axonics, Inc. accounts for 61.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $1,814 and has fallen 88.0% since, to $218 in 2025.
Across 60 payments — averaging $39.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$1K
- Sumitomo Pharma America, Inc.$228
- Boston Scientific$101
- AbbVie$101
- Teleflex LLC$66
- Merck$44
- plus $363 from 15 others
What the payments were for
- Travel & lodging$97341%
- Food & beverage$1,37659%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 14 | $1,448 |
| Sumitomo Pharma America, Inc. | 12 | $228 |
| Boston Scientific | 5 | $101 |
| AbbVie | 4 | $101 |
| Teleflex LLC | 3 | $66 |
| Merck | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Myriad Genetic Laboratories, Inc. | 2 | $39 |
| AstraZeneca | 2 | $35 |
| Johnson & Johnson | 1 | $33 |
| Laborie Medical Technologies Corp. | 2 | $28 |
| Immunitybio, Inc. | 1 | $27 |
| Convatec Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Palette Life Sciences, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Pfizer | 1 | $16 |
| Urovant Sciences Inc | 1 | $15 |
| Procept Biorobotics Corporation | 1 | $13 |
| Foundation Medicine, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$1,096
How this compares
$2,350 in reported general payments places this provider in the 85th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 139 | $90,212 |
| MyrbetriqMirabegron | 71 | $35,142 |
| Tamsulosin Hcl | 513 | $4,272 |
| Solifenacin Succinate | 77 | $2,667 |
| Cefdinir | 155 | $2,591 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 155 | $2,582 |
| Finasteride | 233 | $1,949 |
| Oxybutynin Chloride ErOxybutynin Chloride | 81 | $1,191 |
| NitrofurantoinNitrofurantoin Macrocrystal | 34 | $1,035 |
| Oxybutynin Chloride | 86 | $987 |
| Methenamine Hippurate | 23 | $944 |
| Betamethasone Dipropionate | 12 | $549 |
| Fluconazole | 105 | $498 |
| Ciprofloxacin Hcl | 61 | $400 |
| Dutasteride | 22 | $333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $228 | $90,212139 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $35,14271 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 315 family providers in Alaska.
Other family in Jber
- Erica HeagyAnchorage$249K
- Trisha KernodleAnchorage$60K
- Whitney CarlsonSoldotna$16K
- Randi HallSoldotna$16K
- Kristy BloodFairbanks$7K
- Casey BloodFairbanks$7K
- Marisha DietersAnchorage$6K
- Christine HooverAnchorage$6K
- Teal VingerFairbanks$5K
- Kymberli BrockWasilla$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.